Souhaitez-vous accéder aux communiqués récents ?

Tampa, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Specialty-specific clinical documentation requires more than a generic, automated note taker to truly improve the charting process. Today, Nextech – an...

Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Ophthalmology EMR Software Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Ophthalmology EMR Software...

Delray Beach, FL, Jan. 14, 2026 (GLOBE NEWSWIRE) -- According to MarketsandMarkets™, the global Metaverse Market size is expected to grow from USD 83.9 Billion in 2023 to USD 1,303.4 Billion by 2030...

Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program...

Atavistik Bio to present discovery of JAK2 V617F mutant-selective allosteric Inhibitors for the treatment of myeloproliferative neoplasms at ASH 2025.

Ottawa, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Middle East Digital Health market size is calculated at USD 11.45 billion in 2024, grows to USD 14.07 billion in 2025, and is projected to reach around...

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...

Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) Financing will also support indication...

SHENZHEN, China, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services...

Atavistik Bio today announced the expansion of its leadership team with the appointment of Susan Pandya, M.D., as Chief Medical Officer.